Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41598-021-81629-2 http://scihub22266oqcxt.onion/10.1038/s41598-021-81629-2 33479465!7819970!33479465     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Sci+Rep 2021 ; 11 (1): 2062 Nephropedia Template TP {{tp|p=33479465|t=2021. SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness |pdf=|usr=}}{{33479465}} gab.com Text SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness JO: Sci Rep http://www.kidney.de/pget.php?&tw=1&pmid=33479465 #FOAvip In order to support vaccine development, and to aid convalescent plasma therapy, it would be important to understand the kinetics, timing and persistence of SARS-CoV-2 neutralizing antibodies (NAbs), and their association with clinical disease severity. Therefore, we used a surrogate viral neutralization test to evaluate their levels in patients with varying severity of illness, in those with prolonged shedding and those with mild/asymptomatic illness at various time points. Patients with severe or moderate COVID-19 illness had earlier appearance of NAbs at higher levels compared to those with mild or asymptomatic illness. Furthermore, those who had prolonged shedding of the virus, had NAbs appearing faster and at higher levels than those who cleared the virus earlier. During the first week of illness the NAb levels of those with mild illness was significantly less (p = 0.01), compared to those with moderate and severe illness. At the end of 4 weeks (28 days), although 89% had NAbs, 38/76 (50%) in those with > 90 days had a negative result for the presence of NAbs. The Ab levels significantly declined during convalescence (> 90 days since onset of illness), compared to 4 to 8 weeks since onset of illness. Our data show that high levels of NAbs during early illness associated with clinical disease severity and that these antibodies declined in 50% of individuals after 3 months since onset of illness. Twit Text FOAVip SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness ????Sci Rep http://www.kidney.de/pget.php?&tw=1&pmid=33479465 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33479465 #FOAvip English Wikipedia <ref>{{Cite pmid|33479465}}</ref> SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness #MMPMID33479465 Jeewandara C; Jayathilaka D; Gomes L; Wijewickrama A; Narangoda E; Idampitiya D; Guruge D; Wijayamuni R; Manilgama S; Ogg GS; Tan CW; Wang LF; Malavige GN Sci Rep 2021[Jan]; 11 (1): 2062 PMID33479465show ga In order to support vaccine development, and to aid convalescent plasma therapy, it would be important to understand the kinetics, timing and persistence of SARS-CoV-2 neutralizing antibodies (NAbs), and their association with clinical disease severity. Therefore, we used a surrogate viral neutralization test to evaluate their levels in patients with varying severity of illness, in those with prolonged shedding and those with mild/asymptomatic illness at various time points. Patients with severe or moderate COVID-19 illness had earlier appearance of NAbs at higher levels compared to those with mild or asymptomatic illness. Furthermore, those who had prolonged shedding of the virus, had NAbs appearing faster and at higher levels than those who cleared the virus earlier. During the first week of illness the NAb levels of those with mild illness was significantly less (p = 0.01), compared to those with moderate and severe illness. At the end of 4 weeks (28 days), although 89% had NAbs, 38/76 (50%) in those with > 90 days had a negative result for the presence of NAbs. The Ab levels significantly declined during convalescence (> 90 days since onset of illness), compared to 4 to 8 weeks since onset of illness. Our data show that high levels of NAbs during early illness associated with clinical disease severity and that these antibodies declined in 50% of individuals after 3 months since onset of illness. |Adaptive Immunity/immunology[MESH] |Adult[MESH] |Antibodies, Neutralizing/analysis/*immunology[MESH] |Antibodies, Viral/immunology[MESH] |COVID-19 Serotherapy[MESH] |COVID-19/epidemiology/*immunology/therapy[MESH] |Convalescence[MESH] |Female[MESH] |Humans[MESH] |Immunization, Passive/methods[MESH] |Male[MESH] |Middle Aged[MESH] |Neutralization Tests/methods[MESH] |SARS-CoV-2/*immunology[MESH] |Severity of Illness Index[MESH]SARS-CoV-2 neutralizing antibodies in patients with varying severity o(epmc).pdf DeepDyve Pubget Overpricing